Pasithea Therapeutics Corp. (KTTAW) EBITDA Margin (2022)

Pasithea Therapeutics has disclosed EBITDA Margin across 1 years of filings, most recently posting 2110.77% for Q4 2022.

• In Q4 2022, EBITDA Margin changed N/A year-over-year to 2110.77%; the TTM figure through Dec 2022 stood at 3045.12% (changed N/A YoY), while the FY2022 annual figure was 3045.12%, up 2688060.0% from the prior year.
• EBITDA Margin came in at 2110.77% for Q4 2022 at Pasithea Therapeutics, down from 1944.49% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 1944.49% in Q3 2022 to a low of 22679.43% in Q2 2022.